QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 

   

 

Health Affairs, 25, no. 2 (2006): 437-443
doi: 10.1377/hlthaff.25.2.437
© 2006 by Project HOPE
 
New Online
Disparities in Health:
 * Obama aide on legislation
 * Smedley call to action
 * Shrink regulations first
 * A Real Policy Debate
 * Top 10 HA Articles Of '07
This Article
* Full Text (HTML)
* Reprint (PDF)
* Technical Appendix
* Submit a response to this article
* View responses
* Alert me when this article is cited
* Alert me when eLetters are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in ISI Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via ISI Web of Science (5)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Jacobson, M.
* Articles by Newhouse, J. P.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Jacobson, M.
* Articles by Newhouse, J. P.
Related Collections
* Business Of Health
* Consumer Issues
* Legal/Regulatory Issues
* Medicare
* Pharmaceuticals
* Quality Of Care
* Research And Technology
* Health Spending

Health Tracking

MarketWatch

Does Reimbursement Influence Chemotherapy Treatment For Cancer Patients?

Mireille Jacobson, A. James O’Malley, Craig C. Earle, Juliana Pakes, Peter Gaccione and Joseph P. Newhouse

Before the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003, Medicare reimbursed physicians for chemotherapy drugs at rates that greatly exceeded physicians’ costs for those drugs. We examined the effect of physician reimbursement on chemotherapy treatment of Medicare beneficiaries older than age sixty-five with metastatic lung, breast, colorectal, or other gastrointestinal cancers between 1995 and 1998 (9,357 patients). A physician’s decision to administer chemotherapy to metastatic cancer patients was not measurably affected by higher reimbursement. Providers who were more generously reimbursed, however, prescribed more-costly chemotherapy regimens to metastatic breast, colorectal, and lung cancer patients.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
JCOHome page
S. D. Ramsey
How Should We Pay the Piper When He's Calling the Tune? On the Long-Term Affordability of Cancer Care in the United States
J. Clin. Oncol., January 10, 2007; 25(2): 175 - 179.
[Full Text] [PDF]


Home page
JCOHome page
N. J. Meropol and K. A. Schulman
Cost of Cancer Care: Issues and Implications
J. Clin. Oncol., January 10, 2007; 25(2): 180 - 186.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. B. Bach
Costs of Cancer Care: A View From the Centers for Medicare & Medicaid Services
J. Clin. Oncol., January 10, 2007; 25(2): 187 - 190.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Schrag and M. Hanger
Medical Oncologists' Views on Communicating With Patients About Chemotherapy Costs: A Pilot Survey
J. Clin. Oncol., January 10, 2007; 25(2): 233 - 237.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Reimbursements Sway Oncologists' Drug Choices
Gregory D. Pawelski
Health Affairs, 15 Mar 2006 [Full text]
Selling Cancer Chemotherapy With Concessions Creates Conflicts Of Interest For Oncologists
Gregory D. Pawelski
Health Affairs, 1 Aug 2007 [Full text]


Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help

© 2001-2006 Project HOPE–The People-to-People Organization
Terms and Policies